The jury at the St. Louis court announced its verdict against J&J last month, giving a major blow to the company as it now has to pay about $4.7 billion to 22 women or their loved-ones for the claim that it’s talc caused ovarian cancer.
After the disclosure from AstraZeneca that it’s under Justice Department scrutiny for illegally funding Iraqi terrorism, Roche and Johnson & Johnson revealed similar inquiries from the agency.
Wall Street is unclear whether the U.S. insurance industry will have to pay any costs from the $4.69 billion verdict against Johnson & Johnson granted to customers and their families who alleged that asbestos-adulterated talc leads to ovarian cancer.
Genentech recently won the patent for a psoriasis drug. Unfortunately, Roche’s Genentech unit prosecuted Eli Lilly for violation by claiming their psoriasis drugTalz, infringes on one of their patents.
Johnson & Johnson has once again won in its appeals campaign against talcum powder verdicts. Last year, the company had secured two reversals. In this year, the Missouri Court of Appeals reversed another verdict in Gloria Ristesund’s case worth $55 million, where the court lacked jurisdiction.
It has been stated by the women and their families taking legal actions mentioned that the cancer was caused by decade-long use of J&J’s Baby Powder and other cosmetic. The petitioners have alleged that the company failed to warn consumers about cancer risks in spite of the knowledge that its talc was contaminated with asbestos at least since the 1970s.
Prosecutors have already charged Insys founder John Kapoor and won guilty pleas from two characters in an ongoing kickbacks probe. Now, the Justice Department has escalated the case by joining in with whistleblowers who've detailed a stunning range of techniques the company allegedly used to push its powerful opioid painkiller.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.